Skip to main content
. Author manuscript; available in PMC: 2018 Apr 20.
Published in final edited form as: J Mol Biomark Diagn. 2017 Feb 8;8(2):323. doi: 10.4172/2155-9929.1000323

Figure 1. ROC curves of regression models using the prostate biomarker panel, age and PSA test compared to PSA alone.

Figure 1

1A) Prostate Biomarker Panel (FLNA, FLNB, age and PSA) predicts prostate cancer more accurately than PSA alone between patients with or without prostate cancer (Prostate Biomarker Panel AUC, 0.64 (0.59, 0.69), PSA alone AUC, 0.58). 1B) Prostate biomarker FLNB, Age and PSA discriminates between patients with either Gleason ≤6, or Gleason ≥7, over use of PSA alone (Prostate panel AUC, 0.81, (0.71, 0.9), PSA alone AUC, 0.71). 1C) Prostate biomarker FLNB, Age, PSA and low Gleason score (≤ 6) predicts likelihood of low-risk disease over use of PSA alone (Prostate panel AUC, 0.72 (0.66, 0.78), PSA alone AUC, 0.63). 1D) Prostate biomarkers FLNA, KRT19 and Age with PSA discriminates between prostate cancer and benign prostate hyperplasia over use of PSA alone (Prostate panel AUC, 0.71, (0.60, 0.80), PSA alone AUC, 0.58).